Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and CEO ...

After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy. | After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino ...

Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer materials and fuller coverage of difficult genomic regions with | Version 2 ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate. The biotech ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a drug-drug interaction with an antifungal during a phase 2 trial. The Big Pharma ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...

Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a ...

Volker Herrmann, M.D., has also stepped away from the helm, with Sonata chairman David Khougazian taking the wheel as acting ...